Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $41.70.

Several equities analysts have recently weighed in on PHVS shares. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Morgan Stanley upped their price objective on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Oppenheimer increased their target price on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, Bank of America boosted their price target on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, December 4th.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $26.38 on Friday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.80. The company’s 50 day moving average is $26.71 and its 200 day moving average is $24.96.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris during the 4th quarter worth $35,000. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris in the 3rd quarter worth $75,000. Barclays PLC bought a new position in Pharvaris in the 4th quarter worth $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the fourth quarter valued at $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.